J.P. Morgan analyst Jessica Fye has maintained their bullish stance on BMRN stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jessica Fye’s rating is based on several key considerations regarding BioMarin Pharmaceutical’s current and future prospects. Despite a slight miss in third-quarter revenues, particularly with Voxzogo, management has adjusted their 2025 revenue guidance upwards, indicating confidence in future performance. The removal of the 2027 revenue target, while initially concerning, aligns with market expectations and reflects a realistic approach to future projections.
Moreover, BioMarin’s underlying business is seen as undervalued, with a strong base and potential for growth despite current market skepticism. The company is strategically positioned with a robust pipeline and significant capital for business development, focusing on late-stage assets to drive sustainable growth. This combination of factors, including a healthy enzyme revenue stream and promising developments in their pipeline, supports the Buy rating given by Jessica Fye.
In another report released today, Barclays also maintained a Buy rating on the stock with a $80.00 price target.